Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: A phase I study Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Folate Receptor 1
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms

abstract

  • In this phase I study, farletuzumab administered as an i.v. infusion at doses of 12.5 to 400 mg/m(2) was generally safe and well tolerated in the management of heavily pretreated patients with epithelial ovarian cancer.

publication date

  • November 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-0700

PubMed ID

  • 20855460

Additional Document Info

start page

  • 5288

end page

  • 95

volume

  • 16

number

  • 21